Back to Search Start Over

Clinical trial participation among underserved communities: Insights from the Louisiana Community Engagement Alliance.

Authors :
Craig LS
Sarpong DF
Peacock EM
Theall KP
Williams L
Al-Dahir S
Davis TC
Arnold CL
Williams A
Fields T
Wilson M
Krousel-Wood M
Source :
The American journal of the medical sciences [Am J Med Sci] 2023 Oct; Vol. 366 (4), pp. 254-262. Date of Electronic Publication: 2023 Jul 28.
Publication Year :
2023

Abstract

Background: Diverse, equitable and inclusive participation in clinical research is needed to ensure evidence-based clinical practice and lessen disparities in health outcomes. Yet, clinical trial participation remains critically low in minoritized communities, particularly among Blacks. The Louisiana Community Engagement Alliance against COVID-19 Disparities (LA-CEAL) was launched in response to the disproportionate impact of COVID-19 on Black Louisianans to understand community barriers and preferences and increase inclusive participation in research. This study aims to understand perceptions regarding COVID-19 trial participation among underrepresented Louisianans.<br />Methods: A rapid assessment integrating cross-sectional, surveys among federally qualified health center (FQHC) patients and community residents, and focus group discussions (FGDs) from community representatives was conducted in 2020-2021. Factors and perceptions underlying trial participation were identified using logistic regression models and thematic analyses, respectively.<br />Results: Quantitative findings (FQHC: N=908, mean age=46.6 years, 66.4% Black; community: N=504, mean age=54.2 years, 93.7% Black) indicated that 0.9% and 3.6%, respectively, ever participated in a COVID-19 trial. Doctors/Healthcare providers were most trusted (FQHC=55.1%; community=59.3%) sources of information about trials. Advancing age was associated with increased odds of being very willing to participate (OR <subscript>FQHC</subscript> =1.03, 95% CI 1.02-1.05; OR <subscript>Community</subscript> =1.02, 95% CI 1.00-1.04). Qualitative data (6 FGDs, 29 attendees) revealed limited awareness, experimentation/exploitation-based fears, and minimal racial/ethnic representation among trialists as barriers to participation.<br />Conclusion: COVID-19 trial participation rates were low in our sample. Altruism was a key facilitator to participation; fear, mistrust, and low awareness were predominant barriers. Community-centered approaches, engaging informed providers and trusted community members, may facilitate inclusive trial participation.<br />Competing Interests: Declaration of Competing Interest The authors have no conflicts of interest to disclose.<br /> (Copyright © 2023. Published by Elsevier Inc.)

Details

Language :
English
ISSN :
1538-2990
Volume :
366
Issue :
4
Database :
MEDLINE
Journal :
The American journal of the medical sciences
Publication Type :
Academic Journal
Accession number :
37517691
Full Text :
https://doi.org/10.1016/j.amjms.2023.07.011